About us

Alkalon is a privately owned Danish-Swedish pharmaceutical company engaged in formulation development and supply of over-the-counter medicinal products.

The business operates from its head office in Copenhagen and in-house R&D activities take place in a laboratory in Vejle.

Alkalon's primary focus is launch of a portfolio of new, improved nicotine gum formulations.

We operate in the middle of the pharmaceutical value chain and have entered strategic partnerships and supply agreements with a range of well-known pharmaceutical companies in Europe and elsewhere.

ALKALON RAISE ANOTHER € 1.5 MILLION IN VENTURE CAPITAL

Alkalon A/S has raised a total of DKK 25 million (€ 3.4 million) and established a new development laboratory in Denmark

COPENHAGEN, January 18, 2010. Alkalon today announced that it has closed a financing round raising another DKK 11 million (€ 1.5 million) from its current investors syndicate. This brings the total investment in the company up to DKK 25 million (€ 3.4 million) and will allow Alkalon to operate through 2010–11.

Syndicate content